Companies

Shire: analysis

In this week's View from the Top, Andrew Jack, pharmaceuticals correspondent, and Daniel Garrahan analyse the interview with Angus Russell, chief executive of Shire, the UK-listed drugs group. They focus on comments on Pfizer, R&D in the UK, and charging high prices for orphan drugs.